Revive Therapeutics says nerve agent countmeasure study ‘remains in progress’

Revive Therapeutics (RVVTF) announced an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre. DRDC is evaluating pharmacological compounds, including Bucillamine, that may mitigate nerve agent-induced brain injury. The research study evaluating Bucillamine remains in progress, and the Company is awaiting the final findings, which will be released only with the express authorization of DRDC. Revive will continue to provide updates on the DRDC study as it advances toward completion.